Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla

Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market as patients end their 18-month course of Lilly’s product.